Long duration of anticoagulant activity and protective effects of acharan sulfate in vivo

Thrombosis Research

Volumn 113, Issue 1, 2004, Pages 67-73

  Li, Da Wei ^a   Lee, In Sun ^a   Sim, Joon Soo ^a   Toida, Toshihiko ^b   Linhardt, Robert J ^c   Kim, Yeong Shik ^a  

^a Seoul National University   (South Korea)

^b CHIBA UNIVERSITY   (Japan)

^c RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Acharan sulfate; Activated partial thromboplastin time (aPTT); In vivo; Intravenous administration; Thrombin induced lethality model

Indexed keywords

ACHARAN SULFATE; ANTICOAGULANT AGENT; GLYCOSAMINOGLYCAN; HEPARIN; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; ASSAY; BINDING AFFINITY; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; IN VIVO STUDY; LETHALITY; MALE; MEASUREMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN INTERACTION; RAT; SURFACE PLASMON RESONANCE;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOSAMINOGLYCANS; HEPARIN; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED ICR; RATS; RATS, SPRAGUE-DAWLEY; SNAILS; THROMBIN; TIME FACTORS;

EID: 1842636864     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.02.003     Document Type: Article

References (19)

1. Kim Y.S., Jo Y.Y., Chang I.M., Toida T., Park Y., Linhardt R.J. A new glycosaminoglycan from the giant African snail Achatina fulica. J. Biol. Chem. 271:1996;11750-11755.
2. Jeong J., Toida T., Muneta Y., Kosiishi I., Imanari T., Linhardt R.J.et al. Localization and characterization of acharan sulfate in the body of the giant African snail Achatina fulica. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 130:2001;513-519.
3. Wang H., Toida T., Kim Y.S., Capila I., Hileman R.E., Bernfield M.et al. Glycosaminoglycans can influence fibroblast growth factor-2 mitogenicity without significant growth factor binding. Biochem. Biophys. Res. Commun. 235:1997;369-373.
4. Lee Y.S., Yang H.O., Shin K.H., Choi H.S., Jung S.H., Kim Y.M.et al. Suppression of tumor growth by a new glycosaminoglycan isolated from the African giant snail Achatina fulica. Eur. J. Pharmacol. 465:2003;191-198.
5. Wu S.J., Chun M.W., Shin K.H., Toida T., Park Y., Linhardt R.J.et al. Chemical sulfonation and anticoagulant activity of acharan sulfate. Thromb. Res. 92:1998;273-281.
6. Leadley R.J. Jr., Chi L., Rebello S.S., Gagnon A. Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents. J. Pharmacol. Toxicol. Methods. 43:2000;101-116.
7. Sakai S., Onose J., Nakamura H., Toyoda H., Toida T., Imanari T.et al. Pretreatment procedure for the microdetermination of chondroitin sulfate in plasma and urine. Anal. Biochem. 302:2002;169-174.
8. Huang Y., Toyoda H., Toida T., Imanari T. Determination of chondroitin sulphates in human whole blood, plasma and blood cells by high-performance liquid chromatography. Biomed. Chromatogr. 9:1995;102-105.
9. Das J., Kimball S.D., Reid J.A., Wang T.C., Lau W.F., Roberts D.G.et al. Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues. Bioorg. Med. Chem. Lett. 12:2002;41-44.
10. Zhang F., Fath M., Marks R., Linhardt R.J. A highly stable covalent conjugated heparin biochip for heparin-protein interaction studies. Anal. Biochem. 304:2002;271-273.
11. Bjornsson T.D., Wolfram K.M., Kitchell B.B. Heparin kinetics determined by three assay methods. Clin. Pharmacol. Ther. 31:1982;104-113.
12. Palmieri L., Conte A., Giovannini L., Lualdi P., Ronca G. Metabolic fate of exogenous chondroitin sulfate in the experimental animal. Arzneimittelforschung. 40:1990;319-323.
13. Conte A., de Bernardi M., Palmieri L., Lualdi P., Mautone G., Ronca G. Metabolic fate of exogenous chondroitin sulfate in man. Arzneimittelforschung. 41:1991;768-772.
14. Conte A., Volpi N., Palmieri L., Bahous I., Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung. 45:1995;918-925.
15. Stubbs M.T., Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb. Res. 69:1993;1-58.
16. Sanderson P.N., Huckerby T.N., Nieduszynski I.A. Conformational equilibria of α-L-iduronate residues in disaccharides derived from heparin. Biochem. J. 243:1987;175-181.
17. Rich R.L., Myszka D.G. Advances in surface plasmon resonance biosensor analysis. Curr. Opin. Biotechnol. 11:2000;54-61.
18. Sheehan J.P., Sadler J.E. Molecular mapping of the heparin-binding exosite of thrombin. Proc. Natl. Acad. Sci. U. S. A. 91:1994;5518-5522.
19. Lindahl U., Backström G., Thunberg L., Leder I.G. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc. Natl. Acad. Sci. U. S. A. 77:1980;6551-6555.